白蛋白结合 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-07-26. Numbers and descriptions here follow the published literature rather than marketing material.
Pharmacologically, tirzepatide activates two distinct G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Binding at each target triggers cyclic AMP accumulation and downstream signaling in pancreatic beta cells, adipose tissue and the central nervous system. Because the two pathways overlap only partially, the combined effect on insulin secretion, glucagon suppression and appetite signaling differs from that of selective single-receptor compounds. Affinity is not equal across the two targets, and the clinical meaning of that imbalance remains an area of active study.
Clinical research programs have evaluated tirzepatide in adults with type 2 diabetes and in adults with obesity or excess weight. Trials generally reported reductions in glycated hemoglobin and body weight across treatment periods of several months. Since these studies enrolled defined populations under controlled conditions, the findings describe group averages rather than individual outcomes. Open questions include the durability of effects after treatment stops, variation among subgroups, and the long-term consequences of sustained dual receptor stimulation. Published trial summaries should be consulted for exact measurements rather than secondary accounts.
在生理层面，GIP 与 GLP-1 均为肠道内分泌细胞分泌的肠促胰素，进食后参与胰岛素分泌调节与胃排空抑制。Tirzepatide 通过同时激活这两条信号通路，使胰岛素分泌的葡萄糖依赖性增强，并延缓冲胃排空、降低食欲信号。与单一 GLP-1 激动相比，双靶点作用在血糖控制和体重变化上的效应幅度更大，但具体贡献比例仍在研究之中。
脂肪酸侧链的存在使该肽与血浆白蛋白结合能力增强，从而延长循环半衰期，支持每周一次给药的用药间隔。白蛋白结合同时改变组织分布特征，减慢肾脏清除速度。该设计思路在多种长效肽类药物中被反复采用，属于既定的药代动力学策略。
该化合物的名称与结构由国际非专利名称体系统一维持，不同文献中出现的同义写法主要在拼写顺序或盐形式描述上不同。研究者通常通过受体结合实验、细胞内环磷酸腺苷积累测定以及动物模型来确认其双激动活性。相当一部分分子层面的细节——例如两条受体通路之间的信号交叉作用——尚处于开放问题状态。
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Includes the 39-residue backbone and the attached fatty diacid |
| Molecular weight | Approximately 4813 Da | Average mass; the monoisotopic value is slightly lower |
| Receptor targets | GIP receptor and GLP-1 receptor | Dual engagement defines the pharmacological class |
| Backbone length | 39 amino acids | Sequence modified from native glucose-dependent insulinotropic polypeptide |
| Albumin interaction | Reversible, mediated by the fatty diacid | Slows renal clearance and lengthens circulation time |
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
== documenta 12 == In 2007, Adrià was invited to participate in documenta, "a sort of art world Olympics." Adrià felt like an intruder at the event, saying "artists all over battle all their lives to receive an invitation to display their work at documenta and now I, a cook, am asked to go along!" Organizer Roger Buergel told Adrià that he believed "that to create a new cooking technique was as complicated and challenging as painting a great picture. He said that he sees the work [Adrià] does as a new artistic discipline, that [Adrià's] work shows cuisine should be a new art form." With this notion in mind, Buergel invited him to partake in this prestigious international event held every five years in Kassel, Germany. Adrià decided to take a different approach to this event. With the approval of the documenta committee, he set up his pavilion (i.e., exhibition space) some 850 miles from Kassel in his own restaurant, El Bulli. He believed that in order to truly experience his craft one had to come into his controlled environment because what he does is "ephemeral, it's not moveable, it can't be in a museum" (it was also impractical to move all his equipment there). It was then agreed upon that every day, two names would be selected at random and those names would be the diners who would be able to see his 'pavilion'.
== Axonal degeneration == Although most injury responses include a calcium influx signaling to promote resealing of severed parts, axonal injuries initially lead to acute axonal degeneration (AAD), which is rapid separation of the proximal (the part nearer the cell body) and distal ends within 30 minutes of injury. After separation, dystrophic bulb structures form at both terminals and the transected membranes are sealed. A brief latency phase occurs in the distal segment during which it remains electrically excitable and structurally intact. Degeneration follows with swelling of the axolemma, and eventually the formation of bead-like axonal spheroids. The process takes roughly 24 hours in the PNS, and longer in the CNS. The signaling pathways leading to axolemma degeneration are currently poorly understood. However, research has shown that this AAD process is calcium–independent. Granular disintegration of the axonal cytoskeleton and inner organelles occurs after axolemma degradation. Early changes include accumulation of mitochondria in the paranodal regions at the site of injury. Endoplasmic reticulum degrades and mitochondria swell up and eventually disintegrate. The depolymerization of microtubules occurs and is soon followed by degradation of the neurofilaments and other cytoskeleton components. The disintegration is dependent on ubiquitin and calpain proteases (caused by influx of calcium ion), suggesting that axonal degeneration is an active process and not a passive one as previously misunderstood. Thus the axon undergoes complete fragmentation.
==== Physical health ==== Meta-analyses published between 2013 and 2017 show that exercise is associated with reductions in depressive symptoms, fatigue and QoL plus improvements in attention, hyperactivity, impulsivity, social functioning, schizophrenic symptoms, and verbal fluency in various special populations. However, aerobic exercise has no significant effect on anxiety disorders. In 2005 a study conducted by Andrew Steptow and Michael Marmot at University College London, found that happiness is related to biological markers that play an important role in health. The researchers aimed to analyze whether there was any association between well-being and three biological markers: heart rate, cortisol levels, and plasma fibrinogen levels. The participants who rated themselves the least happy had cortisol levels that were 48% higher than those who rated themselves as the most happy. The least happy subjects also had a large plasma fibrinogen response to two stress-inducing tasks: the Stroop test, and tracing a star seen in a mirror image. Repeating their studies three years later Steptow and Marmot found that participants who scored high in positive emotion continued to have lower levels of cortisol and fibrinogen, as well as a lower heart rate. In Happy People Live Longer (2011), Bruno Frey reported that happy people live 14% longer, increasing longevity 7.5 to 10 years and Richard Davidson's bestseller (2012) The Emotional Life of Your Brain argues that positive emotion and happiness benefit long-term health.
This enhances the investigative capabilities of the CPT on isotopes around the N=Z line with particular emphasis on isotopes of interest to low-energy tests of the electroweak interaction and the rp-process.
== Release == Valve announced Half-Life: Alyx in November 2019. They waited until it was almost complete before announcing it, aiming to avoid the delays of previous games. They were conscious that players, having waited years for a new Half-Life game, might be disappointed by a VR game, and tightly managed the announcement. To promote Alyx, Valve made the prior Half-Life games free on Steam from January 2020 until its release. Valve was due to showcase Alyx at the 2019 Game Awards that December, but canceled hours prior, saying they were "hard at work on the game". Alyx was released on March 23, 2020. It was free to owners of Valve Index headsets or controllers. Valve released a Linux version on May 15, along with Vulkan rendering support for both platforms. A pre-release build was mistakenly released on Steam; it included non-VR developer tools, allowing interactions such as picking up objects and firing weapons. However, most basic interactions, such as pressing buttons or filling Alyx's backpack, could not be completed with mouse-and-keyboard controls. Asked about plans for future Half-Life games, the designer David Speyrer said Valve was willing but were waiting for the reaction to Alyx. Walker said "we absolutely see Half-Life: Alyx as our return to this world, not the end of it". Alyx is included with all Steam Frame headsets, a standalone VR headset released by Valve in September 2026. Valve ported Alyx to run on the Steam Frame's ARM64 processor and optimized it with foveated rendering, whereby resolution is reduced in areas the player is not looking at.
Sources: en.wikipedia.org
==== Responsiveness to ovarian steroids ==== Dimorphism is also found in physiological and behavioral responses to ovarian steroids in adults, where males and females respond to these hormones differently. For example, estrogen receptor sensitivity for different sets of neurons is dimorphic already early on in development. Hypothalamic dimorphism underlies some known behavioral differences in mice, and has known physiological effects in humans, e.g. affecting thermoregulation and metabolism. Although human hypothalami exhibit various sex differences, it is not certain which behaviors are caused, predisposed, and not caused by these. In addition to confounding environmental factors, the hypothalamus also contributes to dimorphic human behaviors where the hypothalamus does not itself cause dimorphism, but rather exhibits conditional, dimorphic responses as part of greater pathways, such as the HPG-axis or the HPA-axis. Estrogen and progesterone can influence gene expression in particular neurons or induce changes in cell membrane potential and kinase activation, leading to diverse non-genomic cellular functions. Estrogen and progesterone bind to their cognate nuclear hormone receptors, which translocate to the cell nucleus and interact with regions of DNA known as hormone response elements (HREs) or get tethered to another transcription factor's binding site. Estrogen receptor (ER) has been shown to transactivate other transcription factors in this manner, despite the absence of an estrogen response element (ERE) in the proximal promoter region of the gene.
Scouting 'Round the World: a book updated every three years with details on all WOSM member organizations; WorldInfo Archived 11 October 2006 at the Wayback Machine: a monthly circular distributed in electronic format with the help of Scoutnet.
KefB/KefC K+ efflux proteins of E. coli (i.e., TC# 2.A.37.1.3 and TC# 2.A.37.1.1, respectively), which may be capable of catalyzing both K+/H+ antiport and K+ uniport, depending on conditions Na+/H+ antiporter of Enterococcus hirae (i.e., NapA, TC# 2.A.37.2.1) K+/H+ antiporter of S. cerevisiae (i.e., Kha1, TC# 2.A.37.4.1). It has been proposed that under normal physiological conditions, these proteins may function by essentially the same mechanism. KefC and KefB of E. coli are responsible for glutathione-gated K+ efflux. Each of these proteins consists of a transmembrane hydrophobic N-terminal domain, and a lesser conserved C-terminal hydrophilic domain. Each protein interacts with a second protein encoded by genes that overlap the gene encoding the primary transporter. The KefC ancillary protein is YabF while the KefB ancillary protein is YheR. These ancillary proteins stimulate transport activity about 10-fold. These proteins are important for cell survival during exposure to toxic metabolites, possibly because they can release K+, allowing H+ uptake. Activation of the KefB or KefC K+ efflux system only occurs in the presence of glutathione and a reactive electrophile such as methylglyoxal or N-ethylmaleimide. Formation of the methylglyoxal-glutathione conjugate, S-lactoylglutathione, is catalyzed by glyoxalase I, and S-lactoylglutathione activates KefB and KefC. H+ uptake (acidification of the cytoplasm) accompanying or following K+ efflux may serve as a further protective mechanism against electrophile toxicity.
Cathinones are typically metabolized in the body through processes such as oxidation, reduction, hydrolysis, and conjugation reactions, primarily occurring in the liver. Consumed orally they undergo extensive first-pass metabolism responsible for significant reduction of activity when taken via this route. Main metabolic pathways have been well established as of now consisting of N-demethylation, β-keto reduction and combination of these resulting in formation of 3-chloroephedrine (dihydro-3-CMC) and N-desmethyl-3-CMC the latter being further reduced to 3-chloronorephedrine (N-desmethyl-dihydro-3-CMC). The dihydro metabolites, being considerably more stable than the parent cathinone, are the most abundant in blood and urine samples. Direct studies on activity of 3-chloroephedrine and 3-chloronorephedrine are lacking.However, by structural and metabolic analogy to closely related compounds such as cathinone, methcathinone, and mephedrone, they are expected to retain modest sympathomimetic activity (primarily norepinephrine-mediated peripheral effects such as vasoconstriction, tachycardia, and mild stimulation) but to exhibit substantially diminished central dopaminergic effects (euphoria and reinforcement) compared with the parent drug. These reduced metabolites likely contribute to prolonged but attenuated cardiovascular or stimulant effects due to their greater stability and higher abundance in circulation.
== Biosynthesis == Cyclic peptides in plants are synthesized via a two-step process; the translation of a linear peptide chain, and its subsequent formation into a cyclic structure through activities of a protease-like enzyme or other ways. Some peptides, such as cyclotides, are gene-coded products obtained by the processing of larger precursor proteins. The generic configuration of the precursor protein consists of an endoplasmic reticulum signal sequence, a non-conserved pro-region, a highly conserved region known as the N-terminal repeat (NTR), the mature cyclotide domain and finally a short hydrophobic C-terminal tail.
Sources: en.wikipedia.org
It is a synthetic peptide that activates both the GIP and GLP-1 receptors, making it a dual agonist. Approved products are given by injection rather than by mouth. It is not a small molecule and does not belong to the older sulfonylurea or thiazolidinedione families.
Engaging two receptors recruits signaling pathways that only partly coincide. This can shift the magnitude of effects on insulin release, glucagon levels and appetite relative to selective agents. Whether the pairing delivers benefits beyond a simple sum of the two is still debated in the literature.
The proportional contribution of each receptor to observed clinical effects has not been fully separated. Long-term consequences of continuous dual stimulation are likewise unclear. Investigators continue to probe these points through laboratory and clinical work.
它属于合成修饰肽，同时激动 GIP 与 GLP-1 两种肠促胰素受体。这类分子通常被称为双重肠促胰素受体激动剂，与选择性 GLP-1 激动剂在靶点范围上不同。